Medoclav

Amoxicillin and Clavulanic Acid, the active ingredient in Medoclav, is a penicillin beta‑lactamase inhibitor combination presented as an intravenous solution for systemic use. It treats a range of bacterial infections in adult and pediatric patients when prescribed by a qualified health professional.

GNH USA supplies Medoclav as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Medoclav is a broad‑spectrum antibacterial that targets bacterial infections of several organ systems.

Respiratory tract infections: effective against pathogens causing community‑acquired pneumonia, sinusitis and bronchitis. Urinary tract infections: clears susceptible Gram‑negative and Gram‑positive uropathogens. Skin and soft tissue infections: treats cellulitis, abscesses and wound infections caused by susceptible bacteria. Intra‑abdominal infections: used for peritonitis and intra‑abdominal sepsis where mixed flora are expected.

Adverse reactions may occur with any intravenous antibiotic. Monitoring and prompt reporting are recommended.

Common Side Effects: - Nausea or vomiting - Diarrhea, including mild loose stools - Rash or mild urticaria - Injection‑site phlebitis or discomfort - Elevated liver transaminases - Headache

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Clostridioides difficile‑associated colitis - Hepatic dysfunction or jaundice - Neutropenia or agranulocytosis - Seizures in patients with renal impairment

Before initiating therapy, clinicians should consider several safety measures.

Assess allergy: confirm no known penicillin or β‑lactamase inhibitor hypersensitivity. Monitor renal function: adjust dosing in patients with reduced creatinine clearance. Observe liver enzymes: watch for hepatic injury during prolonged treatment. Use caution in pregnancy: limited data; weigh maternal benefit against potential fetal risk. Avoid in severe hepatic impairment: risk of accumulation and toxicity. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Drug‑drug interactions can alter efficacy or increase toxicity.

Major Interactions (Avoid): - Methotrexate: increased risk of myelosuppression. - Warfarin: potentiation of anticoagulant effect, requiring INR monitoring. - Oral contraceptives: reduced hormonal efficacy, consider backup contraception.

Moderate Interactions (Monitor Closely): - Probenecid: decreases renal clearance, may raise plasma levels. - Aminoglycosides: additive nephrotoxicity, monitor renal function. - Diuretics: may affect renal excretion, adjust dosing if needed.